Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 182 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Acetylsalicylic acid placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

NCT04809818
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

NCT01069003
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 13, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia

NCT00719537
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin, Placebo Oral Tablet, Progesterone
Drug
Lead sponsor
John Uckele
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 13, 2026, 4:05 PM EDT
Not listed Phase 4 Interventional

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

NCT02660866
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Placebo + background APT + SMT, Vorapaxar 2.08 mg/d + background APT + SMT.
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
40 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 13, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Salicylic Augmentation in Depression

NCT03152409
View directory record Official record
Conditions
Depression, Depressive Disorder, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Aspirin 325mg, Placebo Oral Tablet
Drug
Lead sponsor
Jessica Harder
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Minocycline and Aspirin in the Treatment of Bipolar Depression

NCT01429272
View directory record Official record
Conditions
Bipolar Disorder Depression
Interventions
Minocycline, Aspirin, placebo
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Wichita, Kansas • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 13, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Aspirin in Patients With Vestibular Schwannoma

NCT03079999
View directory record Official record
Conditions
Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
12 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

NCT00809965
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
Interventions
Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
15,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Aggrenox Prevention of Access Stenosis

NCT00067119
View directory record Official record
Conditions
Kidney Failure
Interventions
Aggrenox, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Iowa City, Iowa • Portland, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine

NCT01062360
View directory record Official record
Conditions
Common Cold, Pharyngitis
Interventions
Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine, Acetylsalicylic Acid (Aspirin, BAYE4465), Pseudoephedrine, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Warfarin Versus Aspirin Recurrent Stroke Study

NCT00027066
View directory record Official record
Conditions
Stroke
Interventions
Active Aspirin, Active Warfarin, Aspirin placebo, Warfarin placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years
Enrollment
2,206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

NCT01225562
View directory record Official record
Conditions
Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions
Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
21,379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
250
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Analgesic Efficacy of Fast Release Aspirin

NCT01122602
View directory record Official record
Conditions
Drugs, Investigational
Interventions
Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036), Acetylsalicyclic acid (Aspirin, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Results available

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

NCT01241903
View directory record Official record
Conditions
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions
rosuvastatin, placebo
Drug
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Alternative Options to Minimize Niacin-Induced Flushing

NCT00895193
View directory record Official record
Conditions
Hypercholesterolemia, Flushing
Interventions
Apple pectin, Aspirin 325 mg, Placebo
Other · Drug
Lead sponsor
Patrick Moriarty, MD, FACP, FACC
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

NCT00249795
View directory record Official record
Conditions
Atrial Fibrillation, Cardiovascular Disease
Interventions
Irbesartan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
9,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alcohol Inhibits Drug Metabolism by Carboxylesterases

NCT01708369
View directory record Official record
Conditions
Drug Interactions
Interventions
Placebo, Ethanol, Oseltamivir, Aspirin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

NCT01797575
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aspirin, N-acetyl-cysteine (NAC), Sugar Pill
Drug · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 13, 2026, 4:05 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Aspirin Resistance in Women With Migraine

NCT01257893
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Aspirin (acetylsalicylic acid), Placebo
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine

NCT01248468
View directory record Official record
Conditions
Pain, Migraine
Interventions
Aspirin, acetaminophen and caffeine, Sumatriptan, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Anaheim, California • San Francisco, California • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

NCT00621855
View directory record Official record
Conditions
Coronary Disease
Interventions
placebo, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

Patent Foramen Ovale in Cryptogenic Stroke Study

NCT00697151
View directory record Official record
Conditions
Ischemic Stroke, Patent Foramen Ovale
Interventions
Warfarin, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Oct 13, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

NCT02216357
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease (AERD)
Interventions
Ifetroban, Oral Capsule, Placebo, Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Overland Park, Kansas • West Nyack, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 13, 2026, 4:05 PM EDT